Search

Your search keyword '"Sezer O"' showing total 26 results
Start Over Author "Sezer O" Journal leukemia
26 results on '"Sezer O"'

1. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Author

Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M, Jurczyszyn, A, Ludwig, H, Mellqvist, U-H, Chng, W-J, Pilarski, L, Einsele, H, Hou, J, Turesson, I, Zamagni, E, Chim, C S, Mazumder, A, Westin, J, Lu, J, Reiman, T, Kristinsson, S, Joshua, D, Roussel, M, O'Gorman, P, Terpos, E, McCarthy, P, Dimopoulos, M, Moreau, P, Orlowski, R Z, Miguel, J S, Anderson, K C, Palumbo, A, Kumar, S, Rajkumar, V, Durie, B, and Richardson, P G

Published
2016
Full Text
View/download PDF

2. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

4. Management of treatment-emergent peripheral neuropathy in multiple myeloma

Author

Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, and Sonneveld, P

Published
2012
Full Text
View/download PDF

5. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, and Durie, B G M

Published
2012
Full Text
View/download PDF

7. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Author

Giralt, S, Stadtmauer, E A, Harousseau, J L, Palumbo, A, Bensinger, W, Comenzo, R L, Kumar, S, Munshi, N C, Dispenzieri, A, Kyle, R, Merlini, G, San Miguel, J, Ludwig, H, Hajek, R, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M A, Einsele, H, Barlogie, B, Anderson, K C, Gertz, M, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Richardson, P G, Niesvizky, R, Rajkumar, S V, and Durie, B G M

Published
2009
Full Text
View/download PDF

8. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Author

Palumbo, A, Sezer, O, Kyle, R, Miguel, J S, Orlowski, R Z, Moreau, P, Niesvizky, R, Morgan, G, Comenzo, R, Sonneveld, P, Kumar, S, Hajek, R, Giralt, S, Bringhen, S, Anderson, K C, Richardson, P G, Cavo, M, Davies, F, Bladé, J, Einsele, H, Dimopoulos, M A, Spencer, A, Dispenzieri, A, Reiman, T, Shimizu, K, Lee, J H, Attal, M, Boccadoro, M, Mateos, M, Chen, W, Ludwig, H, Joshua, D, Chim, J, Hungria, V, Turesson, I, Durie, B G M, and Lonial, S

Published
2009
Full Text
View/download PDF

10. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Author

Dispenzieri, A, Kyle, R, Merlini, G, Miguel, J S, Ludwig, H, Hajek, R, Palumbo, A, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Comenzo, R, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Harousseau, J L, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Richardson, P, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Rajkumar, S V, and Durie, B G M

Published
2009
Full Text
View/download PDF

13. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Author

Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, and Hussein, M A

Published
2008
Full Text
View/download PDF

16. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

de Larrea, Fernandez C, Kyle, R A, Durie, B GM, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Blade, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

19. Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladeé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, and Rajkumar, S V

Published
2012
Full Text
View/download PDF

21. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Author

Laubach, J, primary, Garderet, L, additional, Mahindra, A, additional, Gahrton, G, additional, Caers, J, additional, Sezer, O, additional, Voorhees, P, additional, Leleu, X, additional, Johnsen, H E, additional, Streetly, M, additional, Jurczyszyn, A, additional, Ludwig, H, additional, Mellqvist, U-H, additional, Chng, W-J, additional, Pilarski, L, additional, Einsele, H, additional, Hou, J, additional, Turesson, I, additional, Zamagni, E, additional, Chim, C S, additional, Mazumder, A, additional, Westin, J, additional, Lu, J, additional, Reiman, T, additional, Kristinsson, S, additional, Joshua, D, additional, Roussel, M, additional, O'Gorman, P, additional, Terpos, E, additional, McCarthy, P, additional, Dimopoulos, M, additional, Moreau, P, additional, Orlowski, R Z, additional, Miguel, J S, additional, Anderson, K C, additional, Palumbo, A, additional, Kumar, S, additional, Rajkumar, V, additional, Durie, B, additional, and Richardson, P G, additional

Published
2015
Full Text
View/download PDF

23. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

Author

E, Terpos, M A, Dimopoulos, O, Sezer, D, Roodman, N, Abildgaard, R, Vescio, P, Tosi, R, Garcia-Sanz, F, Davies, A, Chanan-Khan, A, Palumbo, P, Sonneveld, M T, Drake, J-L, Harousseau, K C, Anderson, B G M, Durie, Jeffrey, Zonder, Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, Radiology & Nuclear Medicine, and Hematology

Subjects
Cancer Research, medicine.medical_specialty, Pathology, Osteolysis, Bone disease, Bone resorption, Bone remodeling, N-terminal telopeptide, Internal medicine, Medicine, Humans, BIOCHEMICAL MARKERS, Multiple myeloma, Hematology, business.industry, Ossification, International Agencies, International Myeloma Working Group, medicine.disease, Oncology, Biological Markers, Bone Remodeling, medicine.symptom, business, Multiple Myeloma, Biomarkers
Abstract

Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino-and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future. Leukemia (2010) 24, 1700-1712; doi:10.1038/leu.2010.173; published online 2 September 2010

Published
2010

24. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Author

M, Dimopoulos, E, Terpos, R L, Comenzo, P, Tosi, M, Beksac, O, Sezer, D, Siegel, H, Lokhorst, S, Kumar, S V, Rajkumar, R, Niesvizky, L A, Moulopoulos, B G M, Durie, Jeffrey, Zonder, Faculty of Engineering, Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG, and IMWG

Subjects
Paraproteinemias/diagnosis, Technetium Tc 99m Sestamibi, Cancer Research, medicine.medical_specialty, Skeletal survey, diagnosis, Radiography, Paraproteinemias, Context (language use), Bone Neoplasms, Absorptiometry, Photon, Medicine, Humans, Plasmacytoma/diagnosis, Multiple Myeloma/diagnosis, Multiple myeloma, medicine.diagnostic_test, business.industry, imaging, Magnetic resonance imaging, Hematology, Gold standard (test), Bone Neoplasms/diagnosis, medicine.disease, Prognosis, Magnetic Resonance Imaging, Bone scintigraphy, Positron emission tomography, Positron-Emission Tomography, oncology, Radiology, business, Nuclear medicine, Multiple Myeloma, Tomography, X-Ray Computed, Plasmacytoma
Abstract

Several imaging technologies are used for the diagnosis and management of patients with multiple myeloma (MM). Conventional radiography, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear medicine imaging are all used in an attempt to better clarify the extent of bone disease and soft tissue disease in MM. This review summarizes all available data in the literature and provides recommendations for the use of each of the technologies. Conventional radiography still remains the 'gold standard' of the staging procedure of newly diagnosed and relapsed myeloma patients. MRI gives information complementary to skeletal survey and is recommended in MM patients with normal conventional radiography and in all patients with an apparently solitary plasmacytoma of bone. Urgent MRI or CT (if MRI is not available) is the diagnostic procedure of choice to assess suspected cord compression. Bone scintigraphy has no place in the routine staging of myeloma, whereas sequential dual-energy X-ray absorptiometry scans are not recommended. Positron emission tomography/CT or MIBI imaging are also not recommended for routine use in the management of myeloma patients, although both techniques may be useful in selected cases that warrant clarification of previous imaging findings, but such an approach should ideally be made within the context of a clinical trial.

Published
2009

25. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.

Author

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, and Einsele H

Subjects
Adult, Chromosome Deletion, Cytogenetics, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease, HLA Antigens chemistry, Humans, Male, Middle Aged, Proportional Hazards Models, Transplantation Conditioning, Treatment Outcome, Multiple Myeloma genetics, Multiple Myeloma therapy, Transplantation, Homologous
Abstract

This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36-0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.

Published
2019
Full Text
View/download PDF

26. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Author

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, and Avet-Loiseau H

Subjects
Classification, Cytogenetic Analysis, Gene Expression Profiling, Humans, Multiple Myeloma genetics, Prognosis, Genetic Testing methods, Multiple Myeloma classification
Abstract

Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several subtypes of the disease have been identified at the genetic and molecular level. These genetic subtypes are associated with unique clinicopathological features and dissimilar outcome. At the top hierarchical level, myeloma can be divided into hyperdiploid and non-hyperdiploid subtypes. The latter is mainly composed of cases harboring IgH translocations, generally associated with more aggressive clinical features and shorter survival. The three main IgH translocations in myeloma are the t(11;14)(q13;q32), t(4;14)(p16;q32) and t(14;16)(q32;q23). Trisomies and a more indolent form of the disease characterize hyperdiploid myeloma. A number of genetic progression factors have been identified including deletions of chromosomes 13 and 17 and abnormalities of chromosome 1 (1p deletion and 1q amplification). Other key drivers of cell survival and proliferation have also been identified such as nuclear factor- B-activating mutations and other deregulation factors for the cyclin-dependent pathways regulators. Further understanding of the biological subtypes of the disease has come from the application of novel techniques such as gene expression profiling and array-based comparative genomic hybridization. The combination of data arising from these studies and that previously elucidated through other mechanisms allows for most myeloma cases to be classified under one of several genetic subtypes. This paper proposes a framework for the classification of myeloma subtypes and provides recommendations for genetic testing. This group proposes that genetic testing needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results